VolitionRX (VNRX) Q3 2024 earnings summary

Executive summary

• Over 110,000 Nu.Q Vet Cancer Tests sold in the first three quarters of 2024, nearly double the total for 2023, with availability expanded to 17 countries and rapid market penetration in Japan and Poland.

• Commercialization is driven by licensing and distribution agreements with major partners, and active commercial and licensing discussions are ongoing in both human and animal health.

• Significant scientific progress in veterinary and human diagnostics, including lung cancer and sepsis, with multiple manuscripts submitted, new validation studies underway, and key data presented at major conferences.

• Strategic focus on achieving cash neutrality in 2025 through revenue growth, cost reductions, and non-dilutive funding.

• Strengthened Board with appointments of Timothy Still as Chair and Dr. Ethel Rubin as Independent Director, both bringing significant sector experience.

Financial highlights

• Nine-month 2024 revenue reached $1.04 million, a 96% increase year-over-year; Q3 revenue was $475,000, up 187% from Q3 2023, mainly from Nu.Q Vet Cancer Test sales.

• Net loss for Q3 2024 was $5.9 million, a 31% improvement from $8.5 million in Q3 2023, due to reduced personnel and clinical trial costs.

• Operating expenses reduced by 28% compared to the same quarter last year, reflecting effective cost-cutting measures.

• Cash used in operating activities for Q3 2024 was $5.4 million, down 36% year-over-year.

• Cash and cash equivalents at quarter-end were $5.4 million, with $2.2 million in non-dilutive funding committed post-quarter and more expected in Q1 2025.

Outlook and guidance

• Targeting cash neutrality in 2025, with each business pillar expected to support itself from a cash flow perspective, contingent on licensing deals.

• Revenue ramp is expected to continue, though management notes potential lumpiness due to distributor stocking patterns.

• Management expects continued operating losses and negative cash flows as R&D and commercialization efforts persist.

• The company plans to seek additional capital through licensing, grants, and equity or debt offerings to fund operations.

• If additional financing is delayed, priority will be given to clinical validation studies and patent maintenance.